The Fenom Pro® point-of-care breath analyzer measures Fractional Exhaled Nitric Oxide (FeNO) molecules. FeNO is an objective biomarker of allergic airway inflammation, an indicator of asthma and other pulmonary conditions. FeNO testing is recommended in the ATS guidelines. Accurate measurement of FeNO levels helps healthcare professionals to correctly prescribe medicines and adjust treatments to reduce exacerbations – providing better overall care to their patients.
Validate and optimize
Take the guesswork out of allergic asthma
management with the Fenom Pro® system, which
quickly and accurately predicts ICS response
based on the measurement of FeNO levels.
Integrating ongoing FeNO testing alongside
standard asthma care practices can help
harmonize personalized treatment guidance,
dose titration, and patient adherence.
1. TEST - Guide treatment planning
2.TREAT – Predict treatment response
3.TEST – Improve patient adherence
This FeNO-based inflammation control
cycle helps manage treatment for patients
with allergic asthma. Monitoring FeNO
over time can help physicians anticipate
exacerbations, validate seasonal factors
and preemptively adjust treatment.
Fenom Pro Asthma Monitor is a new FeNO testing device
that brings clarity to allergic asthma management at
the point of care. A finely-tuned instrument for guiding
preventative treatment decisions.
Count on the proven technology of
Fenom Pro for dependable test results,
better adherence, and lower costs.
• Accurate results you never have to question:
± 5 ppb or 10% maximum
• Tests do not expire
• In-office testing promotes better adherence